India's top drug maker Ranbaxy Laboratories said on Tuesday its first-quarter net profit nearly tripled on booming exports of generic drugs to the United States.
Joy X-1800 has a 1.76 inch screen, 750 mAh battery, 0.08MP camera.
In a bid to speed up the litigation process, the leading home-grown pharma company Dr Reddy's Laboratories has withdrawn its challenge against GlaxoSmithKline's "compound" patent for anti-nausea drug Zofran.
Pharma major GlaxoSmithKline Pharmaceuticals Ltd has sold its Worli plot for Rs 107.6 crore (Rs 1.08 billion) to I-Ven Realty Ltd, a joint venture between ICICI Venture Funds Management Company Ltd and Oberoi Constructions.
Sales during the quarter under review stood at Rs 9,357 crore, up 12.42 per cent, as against Rs 8,323 crore in the corresponding period of the last fiscal
FIPB had taken up these three proposals in its meeting in August, but the decision on them was kept in abeyance.
The health ministry has formed a committee to consider raising the number of drugs deemed essential and subject to price caps.
Roche has already adapted its business model in India to increase affordable access to drugs and try to stave off trouble from India's patent authorities.
The NPPA letter was issued to GSK on Wednesday.
In the quarter ended September 30, the Pirojsha Godrej-led firm recorded Rs 492 crore net sales, up 49% year-on-year
'You must remember that a career is something you can craft for yourself.' 'But if you want to be a successful leader, you need the organisation and your team to support you.' 'In order to make it all work, you need to be cognisant of the team.' 'You can't be a prima donna. These days, people don't accept that.' 'You can't ride roughshod over people.'
The FIPB, headed by Department of Economic Affairs Secretary Arvind Mayaram, discussed 30 foreign direct investment proposals, including 10 from pharma sector.
Fourth quarter earnings of blue-chips such as Infosys, TCS, Wipro, RIL and inflation data for March will dictate the trend on the bourses in a holiday-shortened week ahead, experts said.
IT major nears $100 bn m-cap, accounts for 61% of the group's combined valuation.
Forex dealers said besides a lower opening in the domestic equity market on fears of a rate hike by the Reserve Bank, higher demand for the American currency from importers put pressure on the rupee but dollar's weakness against other currencies overseas, capped the fall.
Quite a few large- and mid-cap stocks are yet to recover from the note ban, pharma, banking and rural demand-based industries among laggards.
Aurobindo Pharma, Cadila Healthcare and Serum Institute are readying their vaccine candidates.
Both competitive intensity and environmental factors are contributing to the leading oral care brand's pain points
British Prime Minister Theresa May will be in India tomorrow, but Cyrus Mistry will no longer head the Indo-UK CEO forum.
Advertising taglines such as 'Bright in studies, bright in sports' attempted to drive home the message that Bournvita, a chocolate drink, could build a child's mental and physical faculties.
Even as the Supreme Court had recently dismissed the industry's plea against prices fixed by the regulator and its timely implementation, the National Pharmaceutical Pricing Authority has asked companies to pay the overcharged dues with 15 per cent interest.
DRL launched four new products in North America during the previous quarter.
.jpg)
The British drugmaker said the shot, called RTS,S, is intended exclusively for use outside the European Union but will be evaluated by the European Medicines Agency in collaboration with the World Health Organisation.
Horlicks widens brand appeal in increasingly competitive market.
BS Annual Awards 2014: Power-packed jury picks the best 7 of corporate India
Respiratory product paves way for launch in larger markets and greater earnings visibility.
The FDA has stepped up its efforts to ensure drug safety in recent months.
The health drink brand from Mondelez walks the tight rope between tradition and trendy to stay relevant.
Markets end in red; bluechips struggle to keep pace.
Launches cloud-based version of solution to target mid-size clients in life sciences.
Govt bans brands with annual sales worth Rs 3,728 crore.
NPPA suggests expanding the list of essential medicines whose prices are controlled
Last year, traffic jumped 15 times on Snapdeal's 'Big Sale Day' on Oct 6, when it had clocked Rs 1 crore a minute of sales over 10 hours.
The Delhi High Court on Friday stayed the ban on some fixed dose combination (FDC) drugs of Glaxo SmithKline, Wockhardt and Laboratories Griffon but said action against their sale could be taken in the absence of valid sale and marketing licence.
India was the flavour of the year, at least in the FMCG sector, as multinationals hiked stakes in their subsidiaries lured by long term potential of the country, while homegrown executives made their way to top hierarchy of global firms in 2013.
Only Hindustan Unilever and Nestl bucked the trend.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances